Urinary Tract Infections
ESBLs are enzymes that confer resistance to ALL penicillins, cephalosporins, and aztreonam. Risk factors for infection or colonization: recent hospitalization, residence in a long-term care facility, prolonged use of broad spectrum antibiotics. Meropenem 1 g IV q8H should be used for all severe urinary infections if the organism is
Download Urinary Tract Infections
Information
Domain:
Source:
Link to this page:
Documents from same domain
Endocarditis prophylaxis - UCLA Health
asp.mednet.ucla.eduUnrepaired cyanotic CHD, including palliative shunts and conduits Completely repaired congenital heart defect with prosthetic material or a prosthetic device placed either during surgery or by catheter intervention, during the first 6 months after the procedure
Skin and Soft Tissue Infections - University of California ...
asp.mednet.ucla.eduCefazolin 1 g IV q8h . MODERATE INFECTIONS Ertapenem 1g IV q24h . OR Ciprofloxacin 500 mg PO BID / 400 mg IV q12h . PLUS EITHER. Clindamycin 600 mg IV q8h/300 mg PO TID . OR . Metronidazole 500 mg IV/PO TID Avoid fluoroquinolones in patients who were on them as outpatients. If patient at risk for MRSA
Antimicrobial Fundamental Concepts - UCLA Health
asp.mednet.ucla.eduAntimicrobial Fundamental Concepts Pharmacodynamics and Therapeutic Drug Monitoring Pharmacokinetics versus pharmacodynamics Pharmacokinetics mathematically describe the relationship of antibiotic concentration to time. Terminology that is typically associated with pharmacokinetics includes: absorption, distribution,
Extended-infusion piperacillin/tazobactam (Zosyn ...
asp.mednet.ucla.eduGemcitabine Haloperidol Hydroxyzine Idarubicin Mitomycin Mitoxantrone Nalbuphine Prochlorperazine Promethazine Streptozocin Tobramycinb Cisatracuriumc Vancomycind aTable lists known Y-site incompatibilities with pip/tazo, for all other agents, refer to Micromedex for compatibility information
Related documents
ANTIBIOTIC RESISTANCE THREATS
www.cdc.govApr 23, 2013 · Extended spectrum β-lactamase producing Enterobacteriaceae (ESBLs) Vancomycin-resistant . Enterococcus (VRE) Multidrug-resistant . Pseudomonas aeruginosa Drug-resistant Non-typhoidal . Salmonella Drug-resistant . Salmonella. Typhi Drug-resistant . Shigella Methicillin-resistant . Staphylococcus aureus (MRSA) Drug-resistant
Content of an Infection Prevention and Control Plan
apic.org3. Antibiotic resistant organisms- MRSA, VRE, ESBLs, CRE, etc. 4. Communicable disease reporting to health dept. 5. Outbreak investigation plan 6. Antibiogram 7. Reports (to whom sent and how often) VI. TB Exposure Control Plan (can be separate policy) CDC has an evaluation tool on their website A. Risk assessment